46-60 of 334
How KIT D816V Shapes Systemic Mastocytosis Diagnosis and Treatment
Clinician's RoundtableHow KIT D816V Shapes Systemic Mastocytosis Diagnosis and Treatment
Brian P. McDonough, MD, FAAFP
Thanai Pongdee, MD
Survival Outcomes in Squamous Cell Carcinoma of the Anal Canal: POD1UM-303 Data
Project Oncology®Survival Outcomes in Squamous Cell Carcinoma of the Anal Canal: POD1UM-303 Data
Brian P. McDonough, MD, FAAFP
Stacey Cohen, MD
Optimizing cGVHD Treatment Decisions in the Second- and Third-Line Settings
Project Oncology®Optimizing cGVHD Treatment Decisions in the Second- and Third-Line Settings
Charles Turck, PharmD, BCPS, BCCCP
Stephanie Gregory, CNP
Real-World Strategies for Complex cGVHD Treatment Decisions
Project Oncology®Real-World Strategies for Complex cGVHD Treatment Decisions
Brian P. McDonough, MD, FAAFP
Doris M. Ponce, MD, MS
Improving Diagnostic Accuracy in Systemic Mastocytosis
Clinician's RoundtableImproving Diagnostic Accuracy in Systemic Mastocytosis
Alexandria May, PharmD, BCPS
Tracy George, MD
Recognizing TK2d: Key Clinical Signs and Diagnostic Protocols
NeuroFrontiersRecognizing TK2d: Key Clinical Signs and Diagnostic Protocols
Alexandria May, PharmD, BCPS
Kaitlin Batley, MD
- advertisement
Identifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role
NeuroFrontiersIdentifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role
Charles Turck, PharmD, BCPS, BCCCP
Bethany Lussier, MD
Advancing Long-Term Outcomes in Systemic Mastocytosis: The Latest Research
Clinician's RoundtableAdvancing Long-Term Outcomes in Systemic Mastocytosis: The Latest Research
Charles Turck, PharmD, BCPS, BCCCP
Anthony Hunter, MD
Real-World Cases in Squamous Cell Carcinoma of the Anal Canal Care
Project Oncology®Real-World Cases in Squamous Cell Carcinoma of the Anal Canal Care
Brian P. McDonough, MD, FAAFP
Madison Conces, MD
Midhun Malla, MD
Making Mechanism-Based Treatment Decisions in cGVHD
Project Oncology®Making Mechanism-Based Treatment Decisions in cGVHD
Brian P. McDonough, MD, FAAFP
Alicia Lieberman, MD, MS
Examining the Global Genetic Prevalence of TK2d
NeuroFrontiersExamining the Global Genetic Prevalence of TK2d
Brian P. McDonough, MD, FAAFP
Austin Larson, MD
Unpacking the Genetics of Friedreich’s Ataxia
NeuroFrontiersUnpacking the Genetics of Friedreich’s Ataxia
Arnulf Koeppen, MD
- advertisement
Friedreich’s Ataxia: Impact of Frataxin Loss
NeuroFrontiersFriedreich’s Ataxia: Impact of Frataxin Loss
Arnulf Koeppen, MD
Is Friedreich’s Ataxia Developmental or Degenerative?
NeuroFrontiersIs Friedreich’s Ataxia Developmental or Degenerative?
Arnulf Koeppen, MD
SPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
NeuroFrontiersSPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
